Paolo Tarantino shared the following post by Guillermo Villacampa, Biostatistician in the Oncology Data Science Group (OdysSey) at Vall d’Hebron Institute of Oncology (VHIO), adding:
“Outstanding presentation by Marleen Kok!”
Quoting Guillermo Villacampa’s post:
“Marleen Kok presents the ESMO Breast 24 key message in translation research. Excellent presentation! And thank you for the mention of the new HER2DX data.”
Source: Paolo Tarantino/X and Guillermo Villacampa/X
Dr. Paolo Tarantino, MD researcher, holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer. Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a robust publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field. Dr. Tarantino’s dedication and innovative approach contribute significantly to the advancement of breast cancer treatment and research.